Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews

Marc Miravitlles, Mike Herepath, Asim Priyendu, Sheetal Sharma, Tatiana Vilchez, Oliver Vit, Michaela Haensel, Virginie Lepage, Helena Gens, Timm Greulich
European Respiratory Review 2022 31: 210262; DOI: 10.1183/16000617.0262-2021
Marc Miravitlles
1Pneumology Dept, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
2CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Miravitlles
  • For correspondence: marcm@separ.es
Mike Herepath
3Optimal Access Life Science Consulting, Swansea, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asim Priyendu
4Access Consulting, HEOR, Parexel International, Mohali, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheetal Sharma
4Access Consulting, HEOR, Parexel International, Mohali, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana Vilchez
5CSL Behring, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Vit
6CSL Behring, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaela Haensel
7CSL Behring, Marburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginie Lepage
8CSL Behring, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helena Gens
9CSL Behring, Hattersheim, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timm Greulich
10Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-University, Centre for Lung Research (DZL), Marburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timm Greulich
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder characterised by reduced levels of circulating alpha-1 antitrypsin and an increased risk of lung and liver disease. Recent reviews of AATD have focused on diagnosis, epidemiology and clinical management; comprehensive reviews examining disease burden are lacking. Therefore, we conducted literature reviews to investigate the AATD disease burden for patients, caregivers and healthcare systems. Embase, PubMed and Cochrane libraries were searched for AATD publications from database inception to June 2021, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Most published AATD studies were small and short in duration, with variations in populations, designs, measures and outcomes, complicating cross-study comparisons. AATD was associated with significant pulmonary and hepatic morbidity. COPD, emphysema and bronchiectasis were common lung morbidities, where smoking was a key risk factor. Fibrosis and steatosis were the most common liver complications reported in patients with a PiZ allele. Health status analyses suggested a poorer quality of life for AATD patients diagnosed with COPD versus those with non-AATD-associated COPD. The burden for caregivers included loss of personal time due to caring responsibilities, stress and anxiety. AATD was also associated with high direct medical costs and healthcare resource utilisation.

Abstract

AATD is a rare genetic disorder associated with a considerable burden of lung and liver disease and high healthcare resource utilisation. However, available data are scarce and further research is needed to better understand the burden of this disease. https://bit.ly/3IWtQQ1

Introduction

Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder characterised by reduced levels of the proteinase inhibitor alpha-1 antitrypsin (AAT) in the circulation [1]. Individuals with AATD typically have a mutation in the SERPINA1 (or protease inhibitor (Pi)) gene, leading to a change in the structure of the AAT protein [1]. Normal alleles are known as PiM, while the most common deficiency alleles are PiS and PiZ, with PiMS, PiMZ, PiSS, PiSZ and PiZZ genotypes accounting for most variants [2]. >90% of patients with AATD express the PiZZ genotype; however, there are hundreds of rare and ultra-rare genotypes that result in circulating AAT concentrations of <11 µM, including the null/null genotype, which produces no AAT [2, 3]. Worldwide, it has been estimated that there are 3.4 million individuals with deficiency allele combinations (PiZZ, PiSZ or PiSS genotypes), and ⩾116 million carriers of deficiency alleles (i.e. heterozygous for the PiZ and PiS genotypes) [4].

AAT is produced mainly in the liver and circulates to the lungs, where it inhibits neutrophil elastase [5, 6]. If AAT is significantly reduced or absent, excess neutrophil elastase can degrade the lung extracellular matrix, as well as alveolar structures and blood vessels [7]. Individuals with AATD are therefore at increased risk of developing pulmonary disease, especially emphysema, which is often found in the basal areas of the lung [6]. AATD affects males and females equally, and the approximate age of diagnosis is 40–45 years [8].

Some individuals with AATD are prone to developing liver disease, which is secondary to accumulation of mutant AAT in hepatocytes [1, 6]. Patients with the Z variant (both heterozygotes and homozygotes) can develop liver disease due to abnormal folding of the Z AAT protein, which enables individual PiZ AAT proteins to polymerise and aggregate within the endoplasmic reticulum with eventual apoptosis of hepatocytes leading to toxicity, liver injury and increased risk of liver disease [9]. Liver complications are not observed in patients who have the null/null phenotype, because of the lack of aggregation of mutant proteins in the endoplasmic reticulum [10].

Infusion of purified human plasma-derived AAT protein (AAT therapy) has been available to treat AATD since it was first authorised by the United States Food and Drug Administration in 1987. Approval of this therapy was based on biochemical efficacy outcomes, i.e. inhibiting neutrophil elastase activity ex vivo, and maintaining AAT concentrations above presumed therapeutic thresholds in both serum and bronchoalveolar lavage fluid samples in patients with AATD [11]. In 2015, the RAPID trial reported a significantly reduced rate of lung density decline as measured by computed tomography (CT) for AAT therapy versus placebo [12, 13].

Although CT densitometry is useful for evaluating patients’ responses to AATD therapies [14], the assessment of disease severity and progression is conventionally based on pulmonary function tests, such as forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO), where declines over time are largely accepted as indicative of disease progression [2]. These measures can correlate with changes in quality of life (QoL), as measured by QoL instruments specifically designed for patients with obstructive airways disease, such as the St George's Respiratory Questionnaire (SGRQ) [14]. As for most pulmonary diseases, exacerbation severity and frequency can accelerate disease progression in AATD. Dyspnoea is a common complaint among patients with AATD and can be assessed using the modified Medical Research Council (mMRC) dyspnoea scale. These measures provide a means to assess disease burden in patients with AATD, comparing it with observations in patients with non-AATD-associated COPD.

Recent reviews of AATD have focused on the epidemiology and distribution of genetic variants, disease screening, diagnosis and care, as well as AAT therapy [2, 3, 15–19]. In contrast, comprehensive reviews that assess the burden of AATD on patients, caregivers and healthcare systems are lacking. An increased understanding of this burden may help improve awareness and diagnosis rates, as well as healthcare resource planning and allocation. Consequently, we conducted systematic and structured literature reviews to assess the clinical, economic and QoL-related disease burden associated with AATD worldwide.

Methods

Systematic reviews of the AATD literature were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [20]. The objective of this analysis was to assess 1) clinical burden and mortality associated with AATD; 2) QoL for patients; 3) caregiver burden; and 4) healthcare costs and resource utilisation.

Data sources

Embase, MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews and the Essential Reference Tool for Economics Literature were collectively searched from database inception to June 2021 to identify English-language studies on AATD using defined search strategies. Congress proceedings from 2017–2021 were also searched. In addition, registry websites (including the Tufts Cost-effectiveness Analysis Registry, the Alpha-1 Antitrypsin Deficiency Spanish Registry (REDAAT) and EUROCAT) and health technology assessment reports were searched for relevant studies. Finally, relevant systematic reviews identified through database searches were used for bibliography searching.

Population characteristics

The patient population of interest was adults (aged ≥18 years) of any race or gender with AATD. There were no restrictions on inclusion of studies based on intervention and comparator, country or publication timeframe. Publications that included patients with other diseases and studies that enrolled a mixed population of children and adults were excluded if subgroup data for adult patients with AATD were not available.

Search strategy, procedures and information extraction

All titles were downloaded into a systematic review database. Citations obtained from the searches were initially screened by two independent reviewers and conflicts resolved by a third independent reviewer/consensus. Citations that did not match the eligibility criteria were excluded, as were any duplicates due to overlap in coverage of the databases. Full-text papers were then screened in a similar fashion, with any discrepancies between the two reviewers resolved by a third independent reviewer. One reviewer then extracted data into a pre-defined extraction grid, which was validated by another independent reviewer. Where more than one publication was identified as describing a single study, the data were compiled into a single entry to avoid double counting of patients and studies. The search strategies used are shown in the supplementary figures.

Critical appraisal

Critical appraisal of included randomised controlled trials was conducted using comprehensive assessment criteria based on recommendations by the National Institute for Health and Care Excellence [21]. Observational studies were critically appraised using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist [22].

Results

Clinical burden review

A total of 38 studies were included in the clinical burden review (supplementary figure S1), 17 of which were conference abstracts. 23 studies were conducted in Europe; nine in North America; and the remainder did not report the study location. Study sample size ranged from 19 patients in a small case–control study [23] to 422 506 patients from a UK population-based cohort [24]. 31 of the included studies reported clinical characteristics of patients with AATD (supplementary table S1). Mean age ranged from 39.9 to 69.6 years across 29 studies, and the proportion of males was ≥50% in 18 studies. Data on smoking status were reported in 17 studies; in 15 of these, most patients were current or former smokers (52–84%) [25–35]. The remaining two studies involved nonsmoking patients, who comprised all patients in one study [36] and 73% of patients in the other study [29]. PiZZ was the most commonly identified genotype, and was the only genotype identified in 10 studies [25, 27, 30, 31, 37–42].

Of the 38 included studies, all reported data regarding specific morbidities in patients with AATD including pulmonary, liver and skin disease; overall, 50 different morbidities were reported (table 1) [23–30, 32–59]. Pulmonary morbidity was commonly reported, and included COPD with a prevalence of 36.3–75.8% [25, 26, 33, 43, 49], emphysema (14.4–53.8%) [29, 43, 46, 47] and bronchiectasis (3.8–73.1%) (table 1) [29, 45–47].

View this table:
  • View inline
  • View popup
TABLE 1

Clinical burden review: morbidity associated with alpha-1 antitrypsin deficiency (AATD)

One study reported lung nodules in 26.8% of patients [40]. Risk factors for developing lung morbidity in individuals with AATD were reported in 10 studies. Smoking was cited as a risk factor in six studies [26, 35, 47–50], and current smoking, age (40–59 years) and frequent severe exacerbations of COPD were associated with an accelerated decline of FEV1 in individuals with severe AATD [26, 35]. The remaining studies did not examine the influence of smoking on risk.

There are mixed results reported for the influence of genotype on lung disease, with some studies reporting that PiSZ is a risk for exacerbation of lung disease [44, 47], others that PiZZ results in more severe disease [34, 46, 50] and one study reporting no increased risk of COPD due to PiSZ (table 1) [33]. One study reported on the effects of PiSS and PiMM and reported a significant four-fold increase in lung cancer risk in never-smokers with PiSS compared with PiMM genotypes (OR 4.64, 95% CI 1.08–19.92) [36].

Liver fibrosis was the most reported hepatic morbidity, with a wide variation in prevalence (1–88%) in those with AATD [23, 24, 27, 31, 38, 39, 52, 53, 55]. Advanced liver fibrosis was reported in 0.5–25.6% of patients [23, 31, 38, 53]. Cirrhosis was seen in 4–11% of patients [23–25, 37, 56]. A single study reported hepatocellular carcinoma in 2% of patients and hepatitis in 1% [25]. Genotype was an important risk factor for liver morbidity, with PiZZ associated with an increased risk of advanced liver fibrosis [38] and steatosis [53] (table 1). Among individuals with a PiZZ genotype, additional risk factors for liver disease included male sex [25, 38, 39] and the presence of metabolic dysfunction including diabetes [25, 27], metabolic syndrome and obesity [27]. Age >50 years, elevated liver enzyme levels, hepatitis viral infection and COPD were also associated with liver disease [25]. In addition, while PiZZ individuals had more liver stiffness and raised liver enzymes than individuals with an PiMZ or a wild-type PiMM genotype, PiMZ carriers appeared to have an intermediate risk of hepatic morbidity versus those without AATD-associated genotypes [55].

Panniculitis, a neutrophilic inflammation of subcutaneous fat, was reported in <1–8.6% of patients with AATD across three studies [25, 37, 44] (table 1). Other complications associated with AATD included increased psychiatric disorders [59], inflammatory bowel disease [37], venous thromboembolism [30] and cancer [24, 25, 36, 42, 44], and decreased ischaemic heart disease [41].

Mortality

13 publications discussed mortality associated with AATD (table 2) [60–72], four of which were conference abstracts. Four Swedish studies included the same population, although different aspects were analysed [61, 62, 70, 71].

Sample sizes of the studies ranged from 143 to 8039; however, one study examined death certificate records from the United States National Center for Health Statistics, which comprised >26 000 000 cases [64]. In general, these studies showed that mortality in patients with AATD resulted primarily from respiratory diseases, followed by liver complications. The Attaway et al. [60] study, which examined inpatient hospitalisations among patients with AATD, reported an in-hospital mortality rate of 3.1%. One study from Sweden reported a standardised mortality ratio of 3.6 compared with the general population [61], whereas another reported a standardised mortality ratio of 6.3 among National Heart, Lung, and Blood Institute AATD registry patients [63]. Respiratory disease, hepatic disease, diverticulitis and pulmonary embolism were associated with a higher risk of mortality among patients with AATD in the Swedish study [61]. Another study confirmed that patients who were treated with AAT therapy had prolonged survival or time to lung transplantation compared with those who were AAT therapy-naïve [68]. Although patients with the PiZZ genotype had a higher rate of mortality compared with patients without AATD [61, 65, 71], one study observed no difference in mortality rates between never-smoking PiZZ individuals and never-smoking controls [61, 71].

View this table:
  • View inline
  • View popup
TABLE 2

Mortality associated with alpha-1 antitrypsin deficiency (AATD)

Quality of life

The QoL review included 30 studies (supplementary figure S2), 23 of which were journal articles. The sample size ranged from 16 patients [73] to 922 patients [74]. Where reported, the mean age ranged from 40.7 years [14] to 60.3 years [75], and there were more males than females in 19 out of 30 studies, with the proportion of males ranging from 50.3% to 83% (supplementary table S2) [12, 76–78]. Most studies assessed QoL using the SGRQ (22 studies; table 3 [12, 14, 73–76, 78–93]). Other disease-specific patient-reported outcomes included the COPD Assessment Test (CAT), the Chronic Respiratory Disease Questionnaire (CRQ) and the Living with COPD (LCOPD) scale. The generic 36-item short-form survey (SF-36) was used in eight studies and the EQ-5D in two [75, 77] (see supplementary table S2 for the QoL instruments used in each study).

View this table:
  • View inline
  • View popup
TABLE 3

Quality of life review: St George's Respiratory Questionnaire (SGRQ) scores in patients with alpha-1 antitrypsin deficiency (AATD)

Two of the 30 included studies were randomised controlled trials. One of these studies evaluated AAT therapy which used the SGRQ [12] and another that assessed endobronchial valves in patients with AATD which used the SGRQ, mMRC and CAT [86]. The overall STROBE scores [22] among the remaining 24 studies are shown in supplementary table S3.

SGRQ scores (table 3) tended to be worse in patients with AATD who were diagnosed with COPD at baseline versus those with AATD, but without COPD at baseline [12, 88, 90] and in those with frequent exacerbations versus those without [74].

In addition, SGRQ scores were better in patients who never smoked compared with current or former smokers [79, 80, 83]. Several studies examined correlations between SGRQ score, lung function and other measures of physiological decline in AATD [14, 76, 82, 85, 88, 89, 91, 92], while others evaluated the impact of treatment on SGRQ score (table 3 and supplementary table S2) [12, 75, 81, 82].

Finally, a study reported worse QoL among patients with AATD diagnosed with chronic sputum expectoration versus those without chronic sputum expectoration [78].

Among studies reporting CAT scores, one reported similar scores between AATD patients diagnosed with COPD and a non-AATD COPD cohort, despite the AATD group being significantly younger, and having significantly fewer pack-years of smoking and significantly less comorbidity [77]. Regression analysis to assess the relationship between CAT scores and FEV1 showed that the relationship approached statistical significance in the group of AATD patients diagnosed with COPD [77]. A second study reported no significant differences in CAT scores between patients with COPD who were receiving AAT therapy versus those who were not (supplementary table S4) [75].

Other disease-specific measures were reported in several studies. One study reported no differences in LCOPD scores between AATD patients diagnosed with COPD and patients with general COPD (7.2 versus 7.9, p=0.60) [77]. Linear regression analysis showed a significant correlation between FEV1 (%) and LCOPD in both groups with a stronger relationship in AATD patients diagnosed with COPD (r2=0.252, p=0.002 versus r2=0.092, p=0.017 for general COPD) [77]. In another study, patients with AATD-related COPD were found to have a similar level of QoL impairment to patients with AATD and non-AATD-related COPD, but there was no correlation between CRQ scores and FEV1 over time [94].

Six studies evaluated QoL in patients with AATD diagnosed with COPD using the nonspecific SF-36 instrument [74, 87, 89, 91, 92, 95], and two studies evaluated patients with AATD and emphysema with this tool [78, 96] (supplementary tables S2 and S5) [74, 87, 89, 91, 92, 95]. Higher SF-36 scores, indicating better health status, were reported in patients with AATD diagnosed with COPD and a PiZZ genotype (n=30) compared with patients diagnosed with general COPD (n=9) who had the same COPD severity, as measured by FEV1 and DLCO [87]. Exacerbation frequency was associated with significantly poorer SF-36 scores across all domains in patients with AATD diagnosed with COPD receiving AAT therapy [74]. Better QoL was reported for patients with AATD diagnosed with COPD receiving AAT therapy (pulmonary rehabilitation) compared with patients with non-AATD-related COPD [95]. Two studies in patients with AATD diagnosed with COPD suggested that obesity or increased body mass index (BMI) were associated with poorer QoL compared with patients with normal BMI, where obesity was associated with greater comorbidity (table 3) [89, 91]. The association of poorer QoL in patients with a BMI >30 kg·m−2 versus normal BMI was shown to be independent of FEV1 decline in one of these studies [91]. SF-36 scores improved following implementation of comprehensive pulmonary rehabilitation in patients with AATD diagnosed with emphysema awaiting lung transplant [96].

The majority of the papers identified in this review focused on physical aspects of QoL, although mental component scores were reported for the SF-36 questionnaire; most of these were baseline measurements (supplementary table S5) [74, 92, 95]. One study utilising a patient survey reported that patients with severe deficiency were found to have adverse effects on their relationships [97]. No studies within the scope of this review reported on emotional or psychological burden in patients with AATD.

There is no consensus on the difference in QoL burden in patients with AATD with COPD compared with patients with general COPD. No difference between these patient groups was reported in two studies [77, 94]. Better QoL was reported in patients with AATD with COPD versus general COPD in patients with the PiZZ AATD genotype in two studies [87, 95].

Caregiver burden

Five studies were included in the caregiver burden review (supplementary figure S3). The studies were performed in the USA [98–100], Sweden [101] and England (table 4) [102]. All studies were qualitative, with no specific instruments used to measure this burden.

View this table:
  • View inline
  • View popup
TABLE 4

Caregiver burden review: summary of included studies

A review of the key issues for caregivers and family members of patients with AATD reported loss of flexibility in their work and social lives as the partner or spouse was forced to change schedules to provide care [103]. Caregivers also reported anxiety, stress and despair as a result of having to see their diagnosed family members struggling with their condition (table 4) [98, 101, 102]. In addition, some felt guilty that their genetic makeup may have been responsible for the disease in the affected family member, with many reporting fears for future generations [99, 100]. A study examining outcomes 20 years after an AATD neonatal screening programme in Sweden reported more anxiety among mothers of children with AATD than those without [101].

Financial pressure for caregivers in England was reported to result from the need to work reduced hours or taking time off work to attend medical appointments or provide care [102]. There was also concern about the lack of public and healthcare provider knowledge on AATD, as well as a lack of access to information for both patients and caregivers in the USA [99].

Economic burden

The cost and resource use review included 21 studies (supplementary figure S4): 10 were from the USA, and nine out of 21 were presented as conference abstracts. The sample size of studies ranged from five [104] to 9117 [105] patients, and the mean age of AATD patients was 48.3–64.6 years across studies. Where smoking status was reported, patients were typically former smokers (72.9–100%) (supplementary table S6). 14 studies reported the years for which costs were estimated, which ranged from 1997 to 2017 (table 5).

View this table:
  • View inline
  • View popup
TABLE 5

Economic burden review: cost and resource use associated with alpha-1 antitrypsin deficiency (AATD)

Resource use overall was higher in patients with AATD diagnosed with COPD versus those with general COPD [75, 106–108] and those with more severe disease [43]. AlphaNet's Disease Management and Prevention Program in the USA reported greater resource use (primary care, lung specialist visits and hospitalisation) for patients with PiSZ versus PiZZ genotypes who had lung disease, but the authors noted that this may have been due to the latter having better adherence to management recommendations and maintaining a healthier lifestyle [44].

Across studies, the mean length of hospital stay ranged from 2.3 to 8.2 days [60, 75, 109–112] (table 5 [43, 44, 60, 75, 104–121]). The hospitalisation rate and length of stay increased with age [109, 110].

The annual direct medical cost for patients with AATD in the USA was estimated to be USD 127 537 for users of AAT therapy versus USD 15 874 for nonusers [105]. A second US study reported that the median annual total healthcare costs were USD 9753, and the median total medical costs were USD 4927 and total pharmacy costs were USD 2063, although the proportion of patients receiving AAT therapy was not reported [43] (table 5). In Germany, the mean annual direct medical costs per patient were EUR 6099 for users of AAT therapy versus EUR 7117 for nonusers, excluding costs for AAT therapy [75].

Discussion

This review summarises the available evidence on various facets of disease burden in patients with AATD. Based on the studies reviewed, the evidence suggests that AATD is a significant burden for patients, caregivers and healthcare systems. However, the included studies differed greatly in their sample sizes, populations, observational periods, designs, measures and outcomes, making meta-analysis or cross-study comparisons and generalisations difficult.

Many studies in this review included <100 patients, which is expected given the rarity of AATD, and study follow-up also tended to be relatively short, with many prospective studies assessing patients for ≤1 year. Only the larger registries [25, 26, 122] or retrospective, population-based studies [43, 60, 64, 109] were able to include a robust sample size and consider a longer time frame. Moreover, many studies were published only as conference abstracts, particularly those discussing the clinical burden (20 out of 40 studies) and economic burden (nine out of 21), limiting the details available for analysis. Approximately half of all the papers included in this review were published in 2015 or later, particularly those that discussed clinical burden, of which only six studies of clinical burden were published before 2015. Other publications that discussed QoL and costs were ⩾10 years old, with some published in the 1990s. Therefore, the standards of care that are discussed are likely to be outdated. In addition, standards of care and medical costs vary regionally and between countries, making it particularly difficult to compare studies from the USA and Europe that report resource use and costs.

Patients with AATD typically develop pulmonary and hepatic morbidity, and our review suggests that this represents a considerable clinical burden. Among studies reporting lung morbidity in AATD, COPD and emphysema were common (occurring in up to 76% and 54% of patients, respectively). Unsurprisingly, smoking was identified as a key risk factor for the development of lung morbidity in patients with AATD. However, a single study suggested an increased risk of lung cancer in never-smokers with AATD [36]. Fibrosis was the most common liver complication in the studies reviewed here. Risk factors associated with liver fibrosis included male sex, diabetes and age >50 years. Panniculitis is a rare AATD comorbidity that was reported in <1% of patients in two studies reviewed here, whereas in a third study 8.6% of PiZZ patients had skin conditions including panniculitis [25, 37, 44]. The reason for the relatively high prevalence in the third study appears to be the reporting of panniculitis within a general comorbidity of “skin conditions” [44]. There was little consistency between the reporting of mortality rates between the studies [60, 61, 64] (table 2). Mortality data that are derived from index cases of AATD often indicate higher mortality rates compared with the general population; however, the data are difficult to interpret because severely affected individuals are systematically over-represented in registries. Survival was shown to be prolonged among patients with AATD and lung disease who received AAT therapy [68]; however, among never-smokers, there may not be any difference in survival for individuals with a PiZZ genotype versus the general population [69, 71].

Studies reporting QoL in individuals with AATD were heterogeneous, with a variety of disease-specific and generic instruments used across studies. While most studies used the SGRQ, a QoL questionnaire developed for respiratory diseases, many studies used generic QoL measures, including the SF-36, which do not account for parameters that may be unique to patients with AATD, such as having to receive weekly infusions of AAT therapy. Other disease-specific measures that assess dyspnoea and are predictive of survival in COPD, such as the CAT, CRQ and LCOPD scales, were reported in only a few studies. Among studies that used the SGRQ (table 3) and had baseline results, most reported a total mean score >40, indicating moderate impairment of QoL in patients with AATD. In general, worse QoL outcomes were reported for patients with AATD diagnosed with COPD than for patients diagnosed with general COPD, and for current smokers versus never-smokers or former smokers. No studies within the scope of this review reported on emotional or psychological burden in patients with AATD.

Tools used to measure the impact and progression of AATD, including pulmonary function tests (e.g. FEV1) and QoL instruments (e.g. SGRQ) are not sensitive to the small changes that occur over clinically feasible trial periods of 1–3 years in a disease that typically progresses over decades [2, 88]. Trials aimed at detecting a treatment effect over periods of >3 years are impractical to conduct due to the ethical concerns of prolonged placebo exposure and patient retention. Moreover, standards of care could change during study conduct, confounding data interpretation. Recruiting a large enough number of patients, e.g. >1000, to overcome the insensitivity of the measurements is also unfeasible in AATD, given its rarity [123]. The European Respiratory Society statement on AATD reported that a sample size of 550 per treatment group over 3 years would be needed to examine FEV1 decline as an outcome [2]. In addition, data from the UK AATD registry indicated that in order to detect the minimal clinically important difference in SGRQ (a four-point increase), a sufficiently powered, placebo-controlled trial of up to 8 years’ duration would be needed. In addition, this study determined that >8000 patients per treatment arm would be required to detect a 25% reduction in SGRQ score [88].

Patients with AATD and rapid FEV1 decline had worse QoL than those with slower FEV1 decline in one large study (n=772), but not in a second smaller study (n=101) [88, 92]. Clinical disease burden and QoL are likely to be influenced by the rate at which the disease progresses, the sensitivity of progression measurements and the time at which a diagnosis is finally given. Some patients with AATD have been reported to be “fast decliners”, as measured by CT lung density [13] and FEV1 [124]. However, the minimum clinically important difference for either of these outcomes in patients with AATD has not been established [13, 14, 88, 125–128].

Our review suggests that patients with AATD who have frequent exacerbations (≥3 per year) or chronic sputum expectoration have a poorer QoL than patients without [74], and that SGRQ scores may be significantly correlated with both exacerbations and dyspnoea [76]. Exacerbations are often associated with long-term sequelae including significant, permanent loss of lung function [26, 129, 130]. However, exacerbations are random events that are driven by infections and outcomes can vary substantially. The clinical trials conducted so far with either intravenous or inhaled AAT therapy showed inconclusive results in terms of prevention of exacerbations, which may be due to lack of power (or similar) [126, 131]. However, it is important to note that in these studies the event rate and sample sizes were limited, and no plausible mechanism linking the effect to AAT therapy was confirmed.

Our literature search identified limited evidence describing the impact of AATD on the life of caregivers, with only five published studies [98–102]. All studies were qualitative, and no specific instruments were used to measure the burden. This review suggests that caregivers of family members with AATD experience disruption to previously established routines and experience stress and anxiety.

Estimates of the total direct healthcare cost of AATD reviewed here came mainly from the USA and suggested median annual costs of USD 9753 excluding AAT therapy [43]. In Europe, annual costs were approximately EUR 1000 higher for patients who received AAT therapy versus those who did not [75]. The major direct cost drivers were AAT therapy, physician visits and inpatient stays. Little information was available on costs from other countries, making comparisons difficult. Only one study from Germany [75] attempted to estimate indirect costs, highlighting the need for further studies. Resource-use data suggest more annual visits, consultations and longer stays for patients with AATD compared with patients with general COPD and for patients with more severe AATD.

Disease burden is typically measured by the frequency of specific outcomes in a patient population, whether it is change in lung function, QoL or prevalence of a specific morbidity. Only registries can accurately capture such “big data” for AATD. While registries have existed historically, they were mainly national entities that were not centrally coordinated and as a result were not well harmonised in terms of the measurements used and the data collected [132]. Our review found wide variation in the clinical burden and other outcomes for patients with AATD across studies, highlighting the need for more thorough analyses with more consistent measures.

Implications for future research

This review illustrates the difficulties with drawing consistent and meaningful conclusions based on small, variable population samples and study designs. This has serious clinical consequences, as characterising efficacy and safety profiles of treatments is complex in the absence of a clear understanding of the burden, natural history and prognosis of the disease. Hence, there is an urgent need to include all affected patients in a multinational registry based on a consistent and structured reporting framework, and patients, caregivers, healthcare professionals and researchers are urged to form multinational collaborations in order to achieve this. The European Alpha-1 Research Collaboration (EARCO) [133] is seeking to coordinate clinical sites internationally and harmonise methodologies by carrying out quality control of data collection. This registry aims to provide an understanding of the natural history of the disease, to assess the value of AAT therapy in the real world, to evaluate QoL scores and to examine genotypes. This should enable more effective comparative research into the burden of AATD supporting future clinical development, which is an ongoing challenge for rare diseases. In addition, the authors would urge researchers in the field to publish their findings in peer-reviewed journals to increase the impact and reliability of the published literature.

Conclusion

This review found that AATD is associated with a significant clinical and QoL burden, and high direct medical costs and healthcare resource utilisation when compared with the general population. However, there were inconsistencies in the data, with many studies being small, of short duration and with a variety of different measures used for the same outcomes. As a result, considerable gaps in the true burden of this disease remain.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material ERR-0262-2021.SUPPLEMENT

Acknowledgements

Editorial and writing support was provided by Jo Fetterman (Parexel International, Uxbridge, UK) and was funded by CSL Behring GmbH.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Author contributions: All authors contributed to the study design and data interpretation, and reviewed and approved all manuscripts drafts, including the final draft.

  • Conflict of interest: M. Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Palobiofarma SL, Spin Therapeutics, pH Pharma, Novartis, Sanofi and Grifols; and research grants from Grifols.

  • Conflict of interest: M. Herepath is the owner and director of Optimal Access Life Science Consulting Limited.

  • Conflict of interest: A. Priyendu is an employee of Parexel.

  • Conflict of interest: S. Sharma is an employee of Parexel.

  • Conflict of interest: T. Vilchez is an employee of CSL Behring.

  • Conflict of interest: O. Vit is an employee of CSL Behring.

  • Conflict of interest: M. Haensel is an employee of CSL Behring.

  • Conflict of interest: V. Lepage is an employee of CSL Behring.

  • Conflict of interest: H. Gens is an employee of CSL Behring.

  • Conflict of interest: T. Greulich reports personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline and Novartis; grants and personal fees from Grifols; and grants from German Centre for Lung Research (DZL), Marburg, Germany (Deutsches Zentrum für Lungenforschung), all outside the submitted work. The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

  • Support statement: This study was funded by CSL Behring GmbH. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Published in volume 31, issue 163 of the European Respiratory Review on 23 March 2022; republished 31 March 2022 with minor amendments to the layout of tables 1 and 3.

  • Received December 2, 2021.
  • Accepted January 24, 2022.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Torres-Durán M,
    2. Lopez-Campos JL,
    3. Barrecheguren M, et al.
    Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis 2018; 13: 114. doi:10.1186/s13023-018-0856-9
    OpenUrl
  2. ↵
    1. Miravitlles M,
    2. Dirksen A,
    3. Ferrarotti I, et al.
    European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur Respir J 2017; 50: 1700610. doi:10.1183/13993003.00610-2017
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Blanco I,
    2. Diego I,
    3. Bueno P, et al.
    Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. Eur Respir Rev 2020; 29: 200014. doi:10.1183/16000617.0014-2020
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. de Serres FJ
    . Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122: 1818–1829. doi:10.1378/chest.122.5.1818
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ogushi F,
    2. Fells GA,
    3. Hubbard RC, et al.
    Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80: 1366–1374. doi:10.1172/JCI113214
    OpenUrlCrossRefPubMed
  6. ↵
    1. Strnad P,
    2. McElvaney NG,
    3. Lomas DA
    . Alpha1-antitrypsin deficiency. N Engl J Med 2020; 382: 1443–1455. doi:10.1056/NEJMra1910234
    OpenUrl
  7. ↵
    1. Kalfopoulos M,
    2. Wetmore K,
    3. ElMallah MK
    . Pathophysiology of alpha-1 antitrypsin lung disease. Methods Mol Biol 2017; 1639: 9–19. doi:10.1007/978-1-4939-7163-3_2
    OpenUrlCrossRefPubMed
  8. ↵
    1. Stoller JK,
    2. Sandhaus RA,
    3. Turino G, et al.
    Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest 2005; 128: 1989–1994. doi:10.1378/chest.128.4.1989
    OpenUrlCrossRefPubMed
  9. ↵
    1. Karatas E,
    2. Di-Tommaso S,
    3. Dugot-Senant N, et al.
    Overview of alpha-1 antitrypsin deficiency-mediated liver disease. EMJ Hepatol 2019; 7: 65–79.
    OpenUrl
  10. ↵
    1. Rametta R,
    2. Nebbia G,
    3. Dongiovanni P, et al.
    A novel alpha1-antitrypsin null variant (PiQ0Milano). World J Hepatol 2013; 5: 458–461. doi:10.4254/wjh.v5.i8.458
    OpenUrl
  11. ↵
    1. Wewers MD,
    2. Casolaro MA,
    3. Sellers SE, et al.
    Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055–1062. doi:10.1056/NEJM198704233161704
    OpenUrlCrossRefPubMed
  12. ↵
    1. Chapman KR,
    2. Burdon JG,
    3. Piitulainen E, et al.
    Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 360–368. doi:10.1016/S0140-6736(15)60860-1
    OpenUrlCrossRefPubMed
  13. ↵
    1. McElvaney NG,
    2. Burdon J,
    3. Holmes M, et al.
    Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med 2017; 5: 51–60. doi:10.1016/S2213-2600(16)30430-1
    OpenUrl
  14. ↵
    1. Stolk J,
    2. Ng WH,
    3. Bakker ME, et al.
    Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency. Thorax 2003; 58: 1027–1030. doi:10.1136/thorax.58.12.1027
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Quinn M,
    2. Ellis P,
    3. Pye A, et al.
    Obstacles to early diagnosis and treatment of alpha-1 antitrypsin deficiency: current perspectives. Ther Clin Risk Manag 2020; 16: 1243–1255. doi:10.2147/TCRM.S234377
    OpenUrl
    1. McElvaney GN,
    2. Sandhaus RA,
    3. Miravitlles M, et al.
    Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J 2020; 55: 1902410. doi:10.1183/13993003.02410-2019
    OpenUrlAbstract/FREE Full Text
    1. Brantly M,
    2. Campos M,
    3. Davis AM, et al.
    Detection of alpha-1 antitrypsin deficiency: the past, present and future. Orphanet J Rare Dis 2020; 15: 96. doi:10.1186/s13023-020-01352-5
    OpenUrl
    1. Chorostowska-Wynimko J,
    2. Barrecheguren M,
    3. Ferrarotti I, et al.
    New patient-centric approaches to the management of alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2020; 15: 345–355. doi:10.2147/COPD.S234646
    OpenUrl
  16. ↵
    1. Parr DG,
    2. Lara B
    . Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature. Drug Des Devel Ther 2017; 11: 2149–2162. doi:10.2147/DDDT.S105207
    OpenUrlCrossRef
  17. ↵
    1. Liberati A,
    2. Altman DG,
    3. Tetzlaff J, et al.
    The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. doi:10.1136/bmj.b2700
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. National Institute for Health and Care Excellence (NICE)
    . The Guidelines Manual. Process and Methods. London, National Institute for Health and Care Excellence, 2012.
  19. ↵
    1. Vandenbroucke JP,
    2. von Elm E,
    3. Altman DG, et al.
    Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007; 18: 805–835. doi:10.1097/EDE.0b013e3181577511
    OpenUrlCrossRefPubMed
  20. ↵
    1. Arslanow A,
    2. Reichert MC,
    3. Gatter S
    . Simultaneous non-invasive assessment of liver injury and body composition in alpha1-antitrypsin deficiency. J Hepatol 2017; 66: S172. doi:10.1016/S0168-8278(17)30626-8
    OpenUrl
  21. ↵
    1. Fromme M,
    2. Schneider CV,
    3. Pereira V, et al.
    Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut 2022; 71: 415–423. doi:10.1136/gutjnl-2020-323729
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Tanash HA,
    2. Piitulainen E
    . Liver disease in adults with severe alpha-1-antitrypsin deficiency. J Gastroenterol 2019; 54: 541–548. doi:10.1007/s00535-019-01548-y
    OpenUrlPubMed
  23. ↵
    1. Hiller AM,
    2. Piitulainen E,
    3. Jehpsson L, et al.
    Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2019; 14: 1075–1083. doi:10.2147/COPD.S195847
    OpenUrl
  24. ↵
    1. Clark VC,
    2. Marek G,
    3. Liu C, et al.
    Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. J Hepatol 2018; 69: 1357–1364. doi:10.1016/j.jhep.2018.08.005
    OpenUrlCrossRefPubMed
    1. Chakraborty J,
    2. Perbtani YB,
    3. Shuster JJ, et al.
    Predictors of liver disease in adults with alpha 1 antitrypsin deficiency: a single center retrospective analysis. Am J Gastroenterol 2016; 111: S67–S68.
    OpenUrl
  25. ↵
    1. Costa A,
    2. Saraiva R,
    3. Asseiro M
    . Pulmonary disease in intermediate alpha1-antitrypsin deficient patients. Eur Respir J 2017; 50: PA706. doi:10.1183/1393003.congress-2017.PA706
    OpenUrl
  26. ↵
    1. Basil N,
    2. Ekström M,
    3. Piitulainen E, et al.
    Severe alpha-1-antitrypsin deficiency increases the risk of venous thromboembolism. J Thromb Haemost 2021; 19: 1519–1525. doi:10.1111/jth.15302
    OpenUrl
  27. ↵
    1. Pons M,
    2. Núñez A,
    3. Esquinas C, et al.
    Utility of transient elastography for the screening of liver disease in patients with alpha1-antitrypsin deficiency. J Clin Med 2021; 10: 1724. doi:10.3390/jcm10081724
    OpenUrl
  28. ↵
    1. Gupta N,
    2. Gaudreault N,
    3. Thériault S, et al.
    Granularity of SERPINA1 alleles by DNA sequencing in CanCOLD. Eur Respir J 2020; 56: 2000958. doi:10.1183/13993003.00958-2020
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Franciosi AN,
    2. Hobbs BD,
    3. McElvaney OJ, et al.
    Clarifying the risk of lung disease in SZ alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2020; 202: 73–82. doi:10.1164/rccm.202002-0262OC
    OpenUrlCrossRefPubMed
  30. ↵
    1. Piras B,
    2. Ferrarotti I,
    3. Lara B, et al.
    Clinical phenotypes of Italian and Spanish patients with α1-antitrypsin deficiency. Eur Respir J 2013; 42: 54–64. doi:10.1183/09031936.00104712
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Esquinas C,
    2. Serreri S,
    3. Barrecheguren M, et al.
    Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT). Int J Chron Obstruct Pulmon Dis 2018; 13: 1001–1007. doi:10.2147/COPD.S155226
    OpenUrlPubMed
  32. ↵
    1. Torres-Durán M,
    2. Ruano-Ravina A,
    3. Parente-Lamelas I, et al.
    Alpha-1 antitrypsin deficiency and lung cancer risk: a case-control study in never-smokers. J Thorac Oncol 2015; 10: 1279–1284. doi:10.1097/JTO.0000000000000609
    OpenUrl
  33. ↵
    1. Stone H,
    2. Pye A,
    3. Stockley RA
    . Disease associations in alpha-1-antitrypsin deficiency. Respir Med 2014; 108: 338–343. doi:10.1016/j.rmed.2013.10.006
    OpenUrl
  34. ↵
    1. Hamesch K,
    2. Mandorfer M,
    3. Pereira VM, et al.
    Liver fibrosis and metabolic alterations in adults with alpha-1-antitrypsin deficiency caused by the Pi*ZZ mutation. Gastroenterology 2019; 157: 705–719. doi:10.1053/j.gastro.2019.05.013
    OpenUrlPubMed
  35. ↵
    1. Strnad P,
    2. Buch S,
    3. Hamesch KJ, et al.
    Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver fibrosis. Hepatology 2017; 66: 428A–429A.
    OpenUrl
  36. ↵
    1. Subramanian D,
    2. Edgar R,
    3. Ward H, et al.
    Frequency and clinical significance of lung nodules in alpha 1-antitrypsin deficiency (AATD). Am J Respir Crit Care Med 2010; 181: A2884. doi:10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A2884
    OpenUrl
  37. ↵
    1. Tanash H,
    2. Ekström M,
    3. Basil N, et al.
    Decreased risk of ischemic heart disease in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison with the general population. Int J Chron Obstruct Pulmon Dis 2020; 15: 1245–1252. doi:10.2147/COPD.S247377
    OpenUrl
  38. ↵
    1. Hiller A-M,
    2. Ekström M,
    3. Piitulainen E, et al.
    Risk of cancer in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) compared with the Swedish general population. Eur Respir J 2020; 56: Suppl. 64, 1124. doi:10.1183/13993003.congress-2020.1124
    OpenUrlCrossRef
  39. ↵
    1. Herrera EM,
    2. Joseph C,
    3. Brouwer ES, et al.
    Alpha-1 antitrypsin deficiency-associated clinical manifestations and healthcare resource use in the United States. COPD 2021; 18: 315–324. doi:10.1080/15412555.2021.1917532
    OpenUrl
  40. ↵
    1. Choate R,
    2. Mannino DM,
    3. Holm KE, et al.
    Comparing patients with ZZ versus SZ alpha-1 antitrypsin deficiency: findings from AlphaNet's disease management program. Chronic Obstr Pulm Dis 2019; 6: 29–39. doi:10.15326/jcopdf.6.1.2018.0134
    OpenUrl
  41. ↵
    1. Cortese R,
    2. Mennitti MC,
    3. Mariani F, et al.
    Bronchiectasis in patients with alpha1-antitrypsin deficiency: prevalence and characteristics. Eur Respir J 2016; 48: Suppl. 60, PA737. doi:10.1183/13993003.congress-2016.PA737
    OpenUrl
  42. ↵
    1. Araújo D,
    2. Sucena M
    . Association between alpha 1 antitrypsin and bronchiectasis. Eur Respir J 2015; 46: PA1248.
    OpenUrl
  43. ↵
    1. Kawkgi O,
    2. Hamadi Y,
    3. O'Connor E, et al.
    The classification of the SZ phenotype of alpha-1 antitrypsin deficiency in Ireland. Ir J Med Sci 2013; 182: S439. doi:10.1007/s11845-013-0909-y
    OpenUrl
    1. Ferrarotti I,
    2. Ottaviani S,
    3. Gorrini M, et al.
    Database of the Italian Registry for Alpha-1 Antitrypsin Deficiency (AATD): confirmations and controversy surrounding AATD natural history. Am J Respir Crit Care Med 2012; 185: A4358.
    OpenUrl
  44. ↵
    1. Guttmann C,
    2. Lepper PM,
    3. Bachhuber M, et al.
    Alpha1-antitrypsin deficiency: an analysis of patient subgroups of the German registry. Eur Respir J 2011; 38: 3596.
    OpenUrl
  45. ↵
    1. Franciosi AN,
    2. Alkhunaizi MA,
    3. Woodsmith A, et al.
    Alpha-1 antitrypsin deficiency and tobacco smoking: exploring risk factors and smoking cessation in a registry population. COPD 2021; 18: 76–82. doi:10.1080/15412555.2020.1864725
    OpenUrl
    1. Parr DG,
    2. Guest PG,
    3. Reynolds JH, et al.
    Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176: 1215–1221. doi:10.1164/rccm.200703-489OC
    OpenUrlCrossRefPubMed
  46. ↵
    1. Teckman J,
    2. Di Bisceglie A,
    3. Loomba R, et al.
    Clustering at the extremes of mild and severe fibrosis is seen on liver biopsy in preliminary analysis of a multi-center, prospective adult cohort of alpha-1-antitrypsin deficiency. Hepatology 2019; 70: 1173–1174.
    OpenUrl
  47. ↵
    1. Mandorfer M,
    2. Bucsics T,
    3. Hutya V, et al.
    Advanced liver fibrosis is uncommon among adults with alpha 1-antitrypsin deficiency and severe pulmonary manifestation, while heterozygosity for the z allele predisposes for clinically significant portal hypertension. Hepatology 2017; 66: 440A.
    OpenUrl
    1. Black M,
    2. Whitsett M,
    3. Jacobson I, et al.
    Heterozygous alpha-1 antitrypsin deficiency potentiates liver fibrosis with other chronic liver diseases. Mod Pathol 2020; 33: 1504.
    OpenUrl
  48. ↵
    1. Schneider CV,
    2. Hamesch K,
    3. Gross A, et al.
    Liver phenotypes of European adults heterozygous or homozygous for Pi∗Z variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and noncarriers. Gastroenterology 2020; 159: 534–548. doi:10.1053/j.gastro.2020.04.058
    OpenUrlPubMed
  49. ↵
    1. Hakim A,
    2. Moll M,
    3. Qiao D, et al.
    Heterozygosity of the alpha 1-antitrypsin Pi*Z allele and risk of liver disease. Hepatol Commun 2021; 5: 1348–1361. doi:10.1002/hep4.1718
    OpenUrl
    1. Abu Rmilah A,
    2. Fencl R,
    3. Watt K, et al.
    Association of α 1 antitrypsin phenotype and development of advanced liver disease and pulmonary complications before and after liver transplantation. Transplantation 2021; 105: 1576–1584. doi:10.1097/TP.0000000000003390
    OpenUrl
    1. Sapey E,
    2. Yonel Z,
    3. Edgar R, et al.
    The clinical and inflammatory relationships between periodontitis and chronic obstructive pulmonary disease. J Clin Periodontol 2020; 47: 1040–1052. doi:10.1111/jcpe.13334
    OpenUrl
  50. ↵
    1. Mandich N,
    2. Sweeney P,
    3. Hogarth DK
    . Psychiatric diagnosis and alpha one antitrypsin deficiency phenotypes. Am J Respir Crit Care Med 2011; 183: A2988.
    OpenUrl
  51. ↵
    1. Attaway A,
    2. Hatipoglu U,
    3. Majumdar U, et al.
    In-hospital mortality trends for alpha-1 antitrypsin deficiency in the United States. Am J Respir Crit Care Med 2019; 199: A3997.
    OpenUrl
  52. ↵
    1. Tanash HA,
    2. Ekström M,
    3. Wagner P, et al.
    Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden. Int J Chron Obstruct Pulmon Dis 2016; 11: 1663–1669. doi:10.2147/COPD.S109173
    OpenUrl
  53. ↵
    1. Tanash HA,
    2. Nilsson PM,
    3. Nilsson JA, et al.
    Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 2008; 63: 1091–1095. doi:10.1136/thx.2008.095497
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Stoller JK,
    2. Tomashefski J Jr,
    3. Crystal RG, et al.
    Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry. Chest 2005; 127: 1196–1204. doi:10.1378/chest.127.4.1196
    OpenUrlCrossRefPubMed
  55. ↵
    1. Browne RJ,
    2. Mannino DM,
    3. Khoury MJ
    . Alpha 1-antitrypsin deficiency deaths in the United States from 1979–1991. An analysis using multiple-cause mortality data. Chest 1996; 110: 78–83. doi:10.1378/chest.110.1.78
    OpenUrlCrossRefPubMed
  56. ↵
    1. Catterall F,
    2. Anderson D
    . Prevalence of alpha-1 antitrypsin deficiency (AATD) in Greater Glasgow and Clyde (GG&C) and current practises. Eur Respir J 2020; 56: 2431. doi:10.1183/13993003.congress-2020.2431
    OpenUrlCrossRef
    1. Dawkins P,
    2. Wood A,
    3. Nightingale P, et al.
    Mortality in alpha-1-antitrypsin deficiency in the United Kingdom. Respir Med 2009; 103: 1540–1547. doi:10.1016/j.rmed.2009.04.004
    OpenUrlCrossRefPubMed
    1. Dawkins PA,
    2. Dowson LJ,
    3. Guest PJ, et al.
    Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003; 58: 1020–1026. doi:10.1136/thorax.58.12.1020
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Ellis P,
    2. Holm K,
    3. Choate R, et al.
    Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Eur Respir J 2019; 54: PA3383. doi:10.1183/13993003.congress-2019.PA3383
    OpenUrlCrossRef
  58. ↵
    1. Seersholm N,
    2. Kok-Jensen A,
    3. Dirksen A
    . Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax 1994; 49: 695–698. doi:10.1136/thx.49.7.695
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Tanash HA,
    2. Nilsson PM,
    3. Nilsson JA, et al.
    Survival in severe alpha-1-antitrypsin deficiency (PiZZ). Respir Res 2010; 11: 44. doi:10.1186/1465-9921-11-44
    OpenUrlCrossRefPubMed
  60. ↵
    1. Tanash HA,
    2. Ekström M,
    3. Rönmark E, et al.
    Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits. Eur Respir J 2017; 50: 1700198. doi:10.1183/13993003.00198-2017
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. da Costa Dias de Sousa C,
    2. Meira L,
    3. Sucena M
    . Alpha-1 antitrypsin deficiency – a potentially fatal disease. Eur Respir J 2017; 50: PA4463. doi:10.1183/1393003.congress-2017.PA4463
    OpenUrl
  62. ↵
    1. Annunziata A,
    2. Lanza M,
    3. Coppola A, et al.
    Alpha-1 antitrypsin deficiency: home therapy. Front Pharmacol 2021; 12: 575402. doi:10.3389/fphar.2021.575402
    OpenUrl
  63. ↵
    1. Campos MA,
    2. Alazemi S,
    3. Zhang G, et al.
    Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir Med 2009; 103: 1532–1539. doi:10.1016/j.rmed.2009.04.008
    OpenUrlCrossRefPubMed
  64. ↵
    1. Karl FM,
    2. Holle R,
    3. Bals R, et al.
    Costs and health-related quality of life in alpha-1-antitrypsin deficient COPD patients. Respir Res 2017; 18: 60. doi:10.1186/s12931-017-0543-8
    OpenUrl
  65. ↵
    1. Gauvain C,
    2. Mornex JF,
    3. Pison C, et al.
    Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience. COPD 2015; 12: Suppl. 1, 46–51. doi:10.3109/15412555.2015.1022645
    OpenUrl
  66. ↵
    1. Manca S,
    2. Rodriguez E,
    3. Huerta A, et al.
    Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency. COPD 2014; 11: 480–488. doi:10.3109/15412555.2014.898030
    OpenUrl
  67. ↵
    1. Dowson LJ,
    2. Guest PJ,
    3. Stockley RA
    . The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in α1-antitrypsin deficiency (PiZ). Chest 2002; 122: 1247–1255. doi:10.1378/chest.122.4.1247
    OpenUrlCrossRefPubMed
  68. ↵
    1. Bernhard N,
    2. Lepper PM,
    3. Vogelmeier C, et al.
    Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ. Respir Med 2017; 130: 1–8. doi:10.1016/j.rmed.2017.07.004
    OpenUrl
  69. ↵
    1. Piitulainen E,
    2. Mostafavi B,
    3. Tanash HA
    . Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years. Int J Chron Obstruct Pulmon Dis 2017; 12: 495–500. doi:10.2147/COPD.S120241
    OpenUrl
  70. ↵
    1. Luisetti M,
    2. Ferrarotti I,
    3. Corda L, et al.
    Italian registry of patients with alpha-1 antitrypsin deficiency: general data and quality of life evaluation. COPD 2015; 12: Suppl. 1, 52–57. doi:10.3109/15412555.2015.1023393
    OpenUrlCrossRef
  71. ↵
    1. Bradi AC,
    2. Audisho N,
    3. Casey DK, et al.
    Alpha-1 antitrypsin deficiency in Canada: regional disparities in diagnosis and management. COPD 2015; 12: Suppl. 1, 15–21. doi:10.3109/15412555.2015.1021908
    OpenUrl
  72. ↵
    1. Schramm G,
    2. Piitulainen E,
    3. Wollmer P, et al.
    Early signs of COPD in 42 years old individuals with severe alpha-1-antitrypsin deficiency. Eur Respir J 2020; 56: Suppl. 64, 2479. doi:10.1183/13993003.congress-2020.2479
    OpenUrlCrossRef
    1. Sandhaus RA,
    2. Ellis P,
    3. Holm K, et al.
    Augmentation therapy for alpha-1 antitrypsin deficiency: improved survival and quality of life compared to matched augmentation naive controls followed for up to 15 years. Am J Respir Crit Care Med 2020; 201: A2486. doi:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2486
    OpenUrl
  73. ↵
    1. Crossley D,
    2. Stockley J,
    3. Bolton CE, et al.
    Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative. BMJ Open 2020; 10: e036045. doi:10.1136/bmjopen-2019-036045
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Hogarth D
    . Endobronchial valve treatment of severe emphysema in patients with alpha-1 antitrypsin deficiency. Chest 2019; 156: A1771. doi:10.1016/j.chest.2019.08.1540
    OpenUrl
  75. ↵
    1. Durkan E,
    2. Carroll T,
    3. Moyna N, et al.
    Exercise capacity may be more strongly associated with health status in alpha-1 antitrypsin COPD patients than in alpha-1 antitrypsin replete COPD patients. Am J Respir Crit Care Med 2019; 199: A2063. doi:10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A2063
    OpenUrl
  76. ↵
    1. Stockley RA,
    2. Edgar RG,
    3. Starkey S, et al.
    Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies? Respir Res 2018; 19: 137. doi:10.1186/s12931-018-0844-6
    OpenUrlPubMed
  77. ↵
    1. Ponce M,
    2. Sandhaus R,
    3. Campos M
    . The relation of body mass index and health related quality of life in subjects with alpha 1-antitrypsin deficiency and COPD. Am J Respir Crit Care Med 2014; 189: A5782.
    OpenUrl
  78. ↵
    1. Holm KE,
    2. Borson S,
    3. Sandhaus RA, et al.
    Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD 2013; 10: 226–234. doi:10.3109/15412555.2012.719049
    OpenUrl
  79. ↵
    1. Lascano J,
    2. Salathe M,
    3. Alazemi S, et al.
    Relation between body mass index and health-related quality of life in subjects with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2010; 181: A4114. doi:10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A4114
    OpenUrl
  80. ↵
    1. Dawkins PA,
    2. Dawkins CL,
    3. Wood AM, et al.
    Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33: 1338–1344. doi:10.1183/09031936.00061208
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Stone HM,
    2. Edgar RG,
    3. Thompson RD, et al.
    Lung transplantation in alpha-1-antitrypsin deficiency. COPD 2016; 13: 146–152. doi:10.3109/15412555.2015.1048850
    OpenUrlCrossRef
  82. ↵
    1. Knebel AR,
    2. Leidy NK,
    3. Sherman S
    . Health related quality of life and disease severity in patients with alpha-1 antitrypsin deficiency. Qual Life Res 1999; 8: 385–391. doi:10.1023/A:1008945316646
    OpenUrlCrossRefPubMed
  83. ↵
    1. Jarosch I,
    2. Hitzl W,
    3. Koczulla AR, et al.
    Comparison of exercise training responses in COPD patients with and without alpha-1 antitrypsin deficiency. Respir Med 2017; 130: 98–101. doi:10.1016/j.rmed.2017.07.009
    OpenUrl
  84. ↵
    1. Kenn K,
    2. Gloeckl R,
    3. Soennichsen A, et al.
    Predictors of success for pulmonary rehabilitation in patients awaiting lung transplantation. Transplantation 2015; 99: 1072–1077. doi:10.1097/TP.0000000000000472
    OpenUrl
  85. ↵
    1. Stoller JK,
    2. Smith P,
    3. Yang P, et al.
    Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med 1994; 61: 461–467. doi:10.3949/ccjm.61.6.461
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Bruscino N
    . The Coping Strategies of Alpha-1 Deficient Patients and Their Family Caregivers. Walden Dissertations and Doctoral Studies: Walden University, 2019. https://scholarworks.waldenu.edu/dissertations/7275
  87. ↵
    1. Wienke S,
    2. Strange C,
    3. Walker D, et al.
    Social impact identified in and by the alpha-1 antitrypsin deficiency community. Rare Dis Orphan Drugs 2014; 1: 75–82.
    OpenUrl
  88. ↵
    1. Williams PH,
    2. Shore L,
    3. Sineath M, et al.
    Genetics’ influence on patient experiences with a rare chronic disorder: a photovoice study of living with alpha-1 antitrypsin deficiency. Nurs Clin North Am 2013; 48: 627–636. doi:10.1016/j.cnur.2013.09.008
    OpenUrl
  89. ↵
    1. Sveger T,
    2. Thelin T,
    3. McNeil TF
    . Neonatal alpha1-antitrypsin screening: parents’ views and reactions 20 years after the identification of the deficiency state. Acta Paediatr 1999; 88: 315–318. doi:10.1080/08035259950170097
    OpenUrlCrossRefPubMed
  90. ↵
    1. Mahadeva R
    . Alpha-1 Alliance. Alpha-1 Antitrypsin Deficiency Policy Report. England. 2013. https://alpha1.org.uk/alpha-1-alliance/ Date last accessed: 15 August 2021.
  91. ↵
    1. Anzueto A
    . Alpha-1 antitrypsin deficiency-associated chronic obstructive pulmonary disease: a family perspective. COPD 2015; 12: 462–467. doi:10.3109/15412555.2014.974746
    OpenUrl
  92. ↵
    1. Piitulainen E,
    2. Bernspång E,
    3. Björkman S, et al.
    Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human α1-antitrypsin. Eur J Clin Pharmacol 2003; 59: 151–156. doi:10.1007/s00228-003-0589-z
    OpenUrlPubMed
  93. ↵
    1. Sieluk J,
    2. Levy J,
    3. Sandhaus RA, et al.
    Costs of medical care among augmentation therapy users and non-users with alpha-1 antitrypsin deficiency in the United States. Chron Obstr Pulm Dis 2018; 6: 6–16. doi:10.15326/jcopdf.6.1.2017.0187
    OpenUrl
  94. ↵
    1. Greulich T,
    2. Nell C,
    3. Hohmann D, et al.
    The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J 2017; 49: 1600154. doi:10.1183/13993003.00154-2016
    OpenUrlAbstract/FREE Full Text
    1. Zacherle E,
    2. Noone JM,
    3. Runken MC, et al.
    Health care cost and utilization associated with alpha-1 antitrypsin deficiency among a cohort of medicare beneficiaries with COPD. Value Health 2015; 18: A664. doi:10.1016/j.jval.2015.09.2419
    OpenUrl
  95. ↵
    1. Sieluk J,
    2. Slejko JF,
    3. Silverman H, et al.
    Medical costs of alpha-1 antitrypsin deficiency-associated COPD in the United States. Orphanet J Rare Dis 2020; 15: 260. doi:10.1186/s13023-020-01523-4
    OpenUrl
  96. ↵
    1. Aggarwal S,
    2. Kumar S,
    3. Topaloglu O
    . Trends in hospitalization length of stay and costs in patients with alpha 1 antitrypsin deficiency disorder: analysis of US national in-patient data for 2015. Value Health 2018; 21: PRS18.
    OpenUrl
  97. ↵
    1. Blanchette C,
    2. Noone JM,
    3. Roy D, et al.
    Natural progression of alpha-1 antitrypsin deficiency among hospitalized COPD patients in the US. Chest 2015; 148: 497A. doi:10.1378/chest.2281578
    OpenUrl
    1. Barros-Tizón JC,
    2. Torres ML,
    3. Blanco I, et al.
    Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis 2012; 6: 67–78. doi:10.1177/1753465812438387
    OpenUrlCrossRefPubMed
  98. ↵
    1. Dye DE,
    2. Brameld KJ,
    3. Maxwell S, et al.
    The impact of single gene and chromosomal disorders on hospital admissions in an adult population. J Community Genet 2011; 2: 81–90. doi:10.1007/s12687-011-0043-3
    OpenUrlCrossRefPubMed
    1. Rozario N,
    2. Blanchette C,
    3. Howden R, et al.
    The effect of missing a specialty medication dose on total healthcare cost burden. Value Health 2019; 22: S168. doi:10.1016/j.jval.2019.04.712
    OpenUrl
    1. Mullins CD,
    2. Wang J,
    3. Stoller JK
    . Major components of the direct medical costs of α1-antitrypsin deficiency. Chest 2003; 124: 826–831. doi:10.1378/chest.124.3.826
    OpenUrlCrossRefPubMed
    1. Mullins CD,
    2. Huang X,
    3. Merchant S, et al.
    The direct medical costs of α1-antitrypsin deficiency. Chest 2001; 119: 745–752. doi:10.1378/chest.119.3.745
    OpenUrlCrossRefPubMed
    1. Stoller JK,
    2. Brantly M,
    3. Fleming LE, et al.
    Formation and current results of a patient-organized registry for α1-antitrypsin deficiency. Chest 2000; 118: 843–848. doi:10.1378/chest.118.3.843
    OpenUrlCrossRefPubMed
    1. Stone GA,
    2. Blanchette CM,
    3. Stranton D, et al.
    Healthcare cost and utilization before and after diagnosis of alpha-1 antitrypsin deficiency in the United States. Am J Respir Crit Care Med 2020; 201: A6275. doi:10.1164/rccm.202001-0089LE
    OpenUrl
    1. Rueda JD,
    2. Sieluk J,
    3. Sandhaus RA, et al.
    Limitations and challenges of conducting budget impact analyses in rare diseases: a case study of alpha-1 antitrypsin deficiency. Value Health Reg Issues 2020; 23: 70–76. doi:10.1016/j.vhri.2020.04.003
    OpenUrl
    1. Borget I,
    2. Willemin MC,
    3. Pison C, et al.
    Prevalence and burden of alpha-1 antitrypsin deficiency in France: an analysis from the French National Health Database (SNDS). Value Health 2020; 23: S714. doi:10.1016/j.jval.2020.08.1873
    OpenUrl
    1. Sieloff EM,
    2. Rutledge B,
    3. Huffman C, et al.
    National trends and outcomes of genetically inherited non-alcoholic chronic liver disease in the USA: estimates from the National Inpatient Sample (NIS) database. Gastroenterol Rep 2021; 9: 38–48. doi:10.1093/gastro/goaa091
    OpenUrl
  99. ↵
    1. Lee DU,
    2. Fan GH,
    3. Karagozian RS
    . S1039: The clinical outcomes of hospitalized patients with alpha-1-antitrypsin deficiency-related cirrhosis. Am J Gastroenterol 2020; 115: S528.
    OpenUrl
  100. ↵
    1. Alpha-1-Antitrypsin Deficiency Registry Study Group
    . Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998; 158: 49–59. doi:10.1164/ajrccm.158.1.9712017
    OpenUrlCrossRefPubMed
  101. ↵
    1. Schluchter MD,
    2. Stoller JK,
    3. Barker AF, et al.
    Feasibility of a clinical trial of augmentation therapy for α1-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 2000; 161: 796–801. doi:10.1164/ajrccm.161.3.9906011
    OpenUrlPubMed
  102. ↵
    1. Wencker M,
    2. Fuhrmann B,
    3. Konietzko N, et al.
    Longitudinal follow-up of patients with α1-protease inhibitor deficiency before and during therapy with IV α1-protease inhibitor. Chest 2001; 119: 737–744. doi:10.1378/chest.119.3.737
    OpenUrlCrossRefPubMed
  103. ↵
    1. Parr DG,
    2. Stoel BC,
    3. Stolk J, et al.
    Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency. Thorax 2006; 61: 485–490. doi:10.1136/thx.2005.054890
    OpenUrlAbstract/FREE Full Text
  104. ↵
    1. Dirksen A,
    2. Piitulainen E,
    3. Parr DG, et al.
    Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33: 1345–1353. doi:10.1183/09031936.00159408
    OpenUrlAbstract/FREE Full Text
    1. Stolk J,
    2. Stockley RA,
    3. Piitulainen E, et al.
    Relationship between change in lung density and long-term progression of lung function. Am J Respir Crit Care Med 2015; 192: 114–116. doi:10.1164/rccm.201502-0370LE
    OpenUrl
  105. ↵
    1. Barrecheguren M,
    2. O'Hara K,
    3. Wilkens M, et al.
    Research priorities in α1-antitrypsin deficiency: results of a patients’ and healthcare providers’ international survey from the EARCO Clinical Research Collaboration. ERJ Open Res 2020; 6: 00523-02020. doi:10.1183/23120541.00523-2020
    OpenUrl
  106. ↵
    1. Fähndrich S,
    2. Bernhard N,
    3. Lepper PM, et al.
    Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency. Respir Med 2017; 129: 8–15. doi:10.1016/j.rmed.2017.05.011
    OpenUrl
  107. ↵
    1. Bernhard N,
    2. Lepper PM,
    3. Vogelmeier C, et al.
    Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry. Int J Chron Obstruct Pulmon Dis 2017; 12: 1427–1437. doi:10.2147/COPD.S130925
    OpenUrl
  108. ↵
    1. Stolk J,
    2. Tov N,
    3. Chapman KR, et al.
    Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J 2019; 54: 1900673. doi:10.1183/13993003.00673-2019
    OpenUrlAbstract/FREE Full Text
  109. ↵
    1. Miravitlles M,
    2. Chorostowska-Wynimko J,
    3. Ferrarotti I, et al.
    The European Alpha-1 Research Collaboration (EARCO): a new ERS clinical research collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J 2019; 53: 1900138. doi:10.1183/13993003.00138-2019
    OpenUrlAbstract/FREE Full Text
  110. ↵
    1. Greulich T,
    2. Altraja A,
    3. Barrecheguren M, et al.
    Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020; 6: 00181-02019. doi:10.1183/23120541.00181-2019
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 31 Issue 163 Table of Contents
European Respiratory Review: 31 (163)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews
Marc Miravitlles, Mike Herepath, Asim Priyendu, Sheetal Sharma, Tatiana Vilchez, Oliver Vit, Michaela Haensel, Virginie Lepage, Helena Gens, Timm Greulich
European Respiratory Review Mar 2022, 31 (163) 210262; DOI: 10.1183/16000617.0262-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews
Marc Miravitlles, Mike Herepath, Asim Priyendu, Sheetal Sharma, Tatiana Vilchez, Oliver Vit, Michaela Haensel, Virginie Lepage, Helena Gens, Timm Greulich
European Respiratory Review Mar 2022, 31 (163) 210262; DOI: 10.1183/16000617.0262-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Role of air pollutants in airway epithelial barrier dysfunction
  • E-cigarettes and nicotine abstinence
  • Lung imaging in cystic fibrosis
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society